Therapeutic applications of the versatile fatty acid mimetic WY14643

References

• Santilli AA, Scotese AC, Tomarelli RM. A potent antihypercholesterolemic agent: [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643). Experientia. 1974;30(10):1110–1111.
   PubMedGoogle Scholar
• Göttlicher M, Widmark E, Qiao L, et al. Fatty acids activate a chimera oft he clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci. 1992;89(10):4653–4657.
   PubMed Web of Science ®Google Scholar
• Merk D, Zettl M, Steinhilber D, et al. Pirinixic acids: flexible fatty acid mimetics with various biological activities. Future Med Chem. 2015;7(12):1597–1616.
   PubMed Web of Science ®Google Scholar
• Tomarelli RM, Bauman LM, Savini S. Effect of WY-14,643 on cholesterol metabolism in normal and hypercholersterolemic rats. Atherosclerosis. 1978;30:301–311.
   PubMed Web of Science ®Google Scholar
• Johnson TE, Zhang X, Shi S, et al. Statins and PPARα agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol. 2005;208(3):210–221.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Mahler JF, Haseman JK, et al. Unique renal tubule changes induced in rats and mice by the peroxisome proliferators 2,4-dichlorophenoxyacetic acid (2,4-D) and WY-14643. Toxicol Pathol. 2001;29(4):440–450.
   PubMed Web of Science ®Google Scholar
• Larter CZ, Yeh MM, Van Rooyen DM, et al. Peroxisome proliferator-activated receptor-α agonist, Wy 14643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2012;27(2):341–350.
   PubMed Web of Science ®Google Scholar
• Skrypnyk N, Chen X, Hu W, et al. PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res. 2014;74(2):621–631.
   PubMed Web of Science ®Google Scholar
• Jiang B, Huang C, Zhu Q, et al. WY14643 produces anti-depressant-like effects in mice via the BDNF signaling pathway. Psychopharmacology. 2015;232(9):1629–1642.
   PubMed Web of Science ®Google Scholar
• Sauerberg P, Pettersson I, Jeppesen L, et al. Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J Med Chem. 2002;45(4):789–804.
   PubMed Web of Science ®Google Scholar
• Raspé E, Madsen L, Lefebvre AM, et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation. J Lipid Res. 1999;40:2099–2110.
   PubMed Web of Science ®Google Scholar
• Rau O, Syha Y, Zettl H, et al. Α-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma. Arch Pharm Chem Life Sci. 2008;341:191–195.
   PubMed Web of Science ®Google Scholar
• Hall A, Patel T. γ-Secretase modulators: current status and future directions. Prog Med Chem. 2014;53:101–145.
   PubMedGoogle Scholar
• Pettersson M, Stepan A, Kauffman G, et al. Novel γ-secretase modulators for the treatment of Alzheimer’s disease: a review focusing on patents from 2010 to 2012. Expert Opin Ther Pat. 2013;23(10):1349–1366.
   PubMed Web of Science ®Google Scholar
• Klemin S, Calvo RY, Bond S, et al. WY14,643 inhibits human aldose reductase activity. J Enzym Inhib Med Chem. 2006;21(5):569–573.
   PubMed Web of Science ®Google Scholar
• Thomas J, Bramlett KS, Montrose C, et al. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor α (PPARα) versus liver X receptor. J Biol Chem. 2003;278(4):2403–2410.
   PubMed Web of Science ®Google Scholar
• Jurisch-Yaksi N, Sannerud R, Annaert W. A fast growing spectrum of biological functions of γ-secretase in development and disease. Biochim Biophys Acta. 2013;1828(12):2815–2827.
   PubMed Web of Science ®Google Scholar
• Koeberle A, Zettl H, Greiner C, et al. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-Lipoxygenase. J Med Chem. 2008;51(24):8068–8076.
   PubMed Web of Science ®Google Scholar
• Mayeux R, inventor; Columbia University, assignee. Treatment and prevention of Alzheimer’s disease. World intellectual property organization patent WO20082008/086452 A2. 2008 Jan 9.
   Google Scholar
• Simpkins JW, inventor; Universtiy of North Texas Health Science Center at Fort Worth, assignee. Neuroprotective effects of PPARγ agonists against cellular oxidative insults. United States patent US2004/0224995 A1. 2003 May 9.
   Google Scholar
• Connop BP, inventor; Active Pass Pharmaceuticals, Inc., assignee. Compounds, compositions and methods for modulating beta-amyloid production. United States patent US 2003/0191144 A1. 2002 Dec 19.
   Google Scholar
• Gharanei S, Zatyka M, Astuti D, et al. Vacuolar-type H+-ATPase V1A subunit is a molecular partner of wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Hum Mol Gen. 2013;22(2):203–217.
   PubMed Web of Science ®Google Scholar
• Han S, Sidell N, Fisher PB, et al. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells. Clin Cancer Res. 2004;10(6):1911–1919.
   PubMed Web of Science ®Google Scholar
• Nagy Z, inventor; The university of Birmingham, assignee. Treatment of wolfram syndrome-related neurodegeneration. World intellectual property organization patent WO 2014/049366 A1. 2014 Apr 3.
   Google Scholar
• Løvås K, Røst TH, Skorve J, et al. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation. Diabetes Obes Metab. 2009;11(4):304–314.
   PubMed Web of Science ®Google Scholar
• Berge R, Thia medica as, assignee. Use of lipid clearing agents. World intellectual property organization patent WO 2007/011232 A2. 2007 Jan 25.
   Google Scholar
• Scutt A, inventor; University of Sheffield, assignee. Modulation of bone formation. World intellectual property organization patent WO 01/60355 A1. 2001 Aug 23.
   Google Scholar
• Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996;97(3):806–813.
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell. 1999;3:799–804.
   PubMed Web of Science ®Google Scholar
• Mulshine JL, inventor; The United States of America as represented by the Department of Health and Human Services, assignee. Use of lipoxygenase inhibitors and PPAr ligands as anti-cancer therapeutic and intervention agents. United States patent US6,756,399 B2. 2004 Jun 29.
   Google Scholar
• Kuenzli S, Saurat JH. Effect of topical PPARβ/δ and PPARγ agonists on plaque psoriasis. Dermatology. 2003;206(3):252–256.
   PubMed Web of Science ®Google Scholar
• Kippenberger S, inventor; Phenion GmbH&Co. KG, assignee. Use of pirinixinic acid acid and the salts thereof for treating chronic inflammatory diseases. World intellectual property organization patent WO 2005/107874 A2. 2005 Nov 17.
   Google Scholar
• Ferguson M, inventor; Renovo limited, assignee. LXR-antagonists for the prevention, reduction or inhibition of scarring. World intellectual property organization patent WO 2008/078099 A1. 2008 Jul 3.
   Google Scholar
• Barrett KE, inventor; Unilever PLC, assignee. Methods for reducing the effects of stress on skin condition. World intellectual property organization patent WO 2005/058314 A2. 2005 Jun 30.
   Google Scholar
• Kippenberger S, inventor; Johann Wolfgang Goethe-Universität Frankfurt am Main, assignee. Activators of peroxisome proliferator activated receptors αβ in treatment of skin diseases with immunol. Basis and graft rejection. Offenlegungsschrift patent DE 100 53 003 A1. 2001 Jun 28.
   Google Scholar
• Elias PM, inventor; The regents of the University of California, assignee. Treatment of skin conditions by use of PPARα activators. United States patent US 6,060,515. 1999 Jun 16.
   Google Scholar
• Clark AF, inventor; Alcon, Inc., assignee. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents. World intellecutal propterty organization patent WO2005/060542 A2. 2005 Jul 7.
   Google Scholar
• Drace CD, inventor; Alcon, Inc., assignee. Use of agents that down-regulate expression of tanis and/or p21waf1/cip1/sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21waf1/cip1/sd1 genes. United States patent application publication US 2005/0137123 A1. 2005 Jun 23.
   Google Scholar
• Sharif NA, inventor; Alcon, Inc., assignee. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance. United States patent application publication US 2005/0137122 A1. 2005 Jun 23.
   Google Scholar
• Bertrand E, inventor; Novartis Pharma GmbH, assignee. Disease associated genes. World intellectual property organization patent WO 2005/051413 A2. 2005 Jun 9.
   Google Scholar
• De Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23(6):1444–1451.
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, inventors; the trustees of columbia university in the city of New York, assignee. Methods for treating and preventing cardiac dysfunction in septic shock. World intellectual property organization patent WO 2012/115987 A2. 2012 Aug 30.
   Google Scholar
• Hattori Y, Akimoto K, Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun. 2000;273(3):1144–1149.
   PubMed Web of Science ®Google Scholar
• Consigny P, inventor; Abbott cardiovascular systems Inc., assignee. Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders. World intellectual property organization patent WO 2008/011093 A2. 2008 Jan 24.
   Google Scholar
• Zahradka P, inventor; Ade & company, assignee. Use of PPAR alpha agonists fort he treatment of vascular and renal diseases. World intellectual property organization patent WO 03/075911 A1. 2003 Sep 18.
   Google Scholar
• Konstantopoulos K, inventor; Johns Hopkins University, assignee. Phase 2 inducers and related signaling pathways protect cartilage against inflammation, apoptosis and stress. World intellectual property organization patent WO 2007/130353 A2. 2007 Nov 15.
   Google Scholar
• Forrest MJ, inventor; Merck & Co., Inc., assignee. A method for treating inflammatory diseases by administering a PPAR-delta agonist. World intellectual property organization patent WO 02/100351 A2. 2002 Dec 19.
   Google Scholar
• Lee C-H, inventor; President and fellows of Harvard College, assignee. Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist. World intellectual propertys organization patent WO 2013/134626 A1. 2013 Sep 12.
   Google Scholar
• Krezel W, inventor; Institut national de la santé et de la recherche médicinale, assignee. Methods for induction, predictive diagnosis, and treatment of affective behaviors by modulation of PPAr and RXR receptors. World intellectual property organization patent WO 2011/141822 A2. 2011 Nov 17.
   Google Scholar
• Piomelli D, inventor; The regents of the University of California, assignee. Compounds and methods for treating non-inflammatory pain using PPARalpha agonists. World intellectual property organization patent WO 2005/115370 A2. 2005 Dec 8.
   Google Scholar
• Hu Y, Bajorath J. Compound promiscuity: what can we learn from current data? Drug Discov Today. 2013;18(13–14):644–650.
   PubMed Web of Science ®Google Scholar